Novartis gene therapy is cost effective at up to $900,000: U.S. group

An experimental gene therapy for spinal muscular atrophy (SMA) developed by Swiss drugmaker Novartis AG would offer value at a price of $310,000 to $900,000, according an independent U.S. nonprofit organization that reviews the value of drugs and medical treatments.